UPDATE 1-J&J says its diabetes drug should have same survival edge as Lilly's

Oct 13 (Reuters) - Johnson & Johnson said the proven ability of Eli Lilly and Co's rival Jardiance diabetes drug to save lives in a large clinical trial is a benefit that will likely be seen in the entire class of drugs, including J&J's own approved Invokana treatment.